HIV Research Impact Factor
HIV represents human
immunodeficiency infection. The
infection can prompt
AIDS or
AIDS if not rewarded. Dissimilar to some different infections, the human body can't dispose of HIV totally, even with treatment. So once you get HIV, you have it forever. HIV assaults the body's invulnerable framework, explicitly the CD4
cells (T cells), which help the safe framework fend off diseases. Untreated, HIV lessens the quantity of CD4
cells (T cells) in the body, making the individual bound to get different contaminations or disease related malignant growths. After some time, HIV can devastate such huge numbers of these
cells that the body can't fend off contaminations and sickness. These entrepreneurial contaminations or malignant growths exploit an exceptionally powerless insusceptible framework and sign that the individual has AIDS, the last phase of HIV disease. No viable fix right now exists, however with appropriate clinical consideration, HIV can be controlled. The medication used to treat HIV is called
antiretroviral treatment or ART. On the off chance that individuals with HIV accept ART as recommended, their viral burden (measure of HIV in their blood) can get imperceptible. On the off chance that it remains imperceptible, they can live long, sound lives and have viably no danger of transmitting HIV to a HIV-negative accomplice through sex. Prior to the presentation of ART in the mid-1990s, individuals with HIV could advance to
AIDS in only a couple of years. Today, somebody determined to have HIV and rewarded before the malady is far cutting edge can live close to as long as somebody who doesn't have HIV.
High Impact List of Articles
-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
A review of rifapentine for treating active and latent tuberculosis
Michelle K Haas, Robert W Belknap
Review Article: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Non-inferiority designs and novel antimicrobials
Giorgio Tarchini
Editorial: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neoadjuvant chemotherapy in bladder cancer
Christopher M Tully, Gopa Iyer, Dean F Bajorin
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapies for fragile X syndrome: current state and future direction of clinical trials in humans
Christoph Kamm
Review: Clinical Trail Outcomes: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
Relevant Topics in Clinical